Genmab A/S logo

GMAB - Genmab A/S Share Price

DKK2221 16.0  0.7%

Last Trade - 12:16pm

Large Cap
Market Cap £17.52bn
Enterprise Value £16.01bn
Revenue £1.26bn
Position in Universe 35th / 1789
Unlock GMAB Revenue
Relative Strength (%)
1m -1.38%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -10.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
850.4 1,133 1,816 2,365 3,025 5,366 9,614 7,862 +44.5%
+297.2 +143.9 +47.3 -6.3 +31.8 +43.5 +108.2 -43.0
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Genmab A/Srevenues increased from DKR1.36B to DKR6.34B. Net incomeincreased from DKR157.1M to DKR3.65B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Interest and other financial income increase of 85% toDKR83M (income), Foreign Exchange Gain/Loss–Non-Businessincrease of 37% to DKR36M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GMAB
Graphical History


GMAB Revenue Unlock GMAB Revenue

Net Income

GMAB Net Income Unlock GMAB Revenue

Normalised EPS

GMAB Normalised EPS Unlock GMAB Revenue

PE Ratio Range

GMAB PE Ratio Range Unlock GMAB Revenue

Dividend Yield Range

GMAB Dividend Yield Range Unlock GMAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GMAB EPS Forecasts Unlock GMAB Revenue
Profile Summary

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 11, 1998
Public Since October 1, 2000
No. of Shareholders: 65,525
No. of Employees: 636
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone,
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 65,361,716
Free Float (0.0%)
Eligible for
GMAB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GMAB
Upcoming Events for GMAB
Wednesday 4th November, 2020
Q3 2020 Genmab A/S Earnings Release
Wednesday 4th November, 2020
Q3 2020 Genmab A/S Earnings Call
Friday 13th November, 2020
Genmab A/S Virtual Capital Markets Day
Wednesday 17th February, 2021 Estimate
Q4 2020 Genmab A/S Earnings Release
Friday 26th March, 2021 Estimate
Genmab A/S Annual Shareholders Meeting
Frequently Asked Questions for Genmab A/S
What is the Genmab A/S share price?

As of 12:16pm, shares in Genmab A/S are trading at DKK2221, giving the company a market capitalisation of £17.52bn. This share price information is delayed by 15 minutes.

How has the Genmab A/S share price performed this year?

Shares in Genmab A/S are currently trading at DKK2221 and the price has moved by 53.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genmab A/S price has moved by 74.16% over the past year.

What are the analyst and broker recommendations for Genmab A/S?

Of the analysts with advisory recommendations for Genmab A/S, there are there are currently 5 "buy" , 7 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Genmab A/S is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Genmab A/S next release its financial results?

Genmab A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Genmab A/S dividend yield?

Genmab A/S does not currently pay a dividend.

Does Genmab A/S pay a dividend?

Genmab A/S does not currently pay a dividend.

When does Genmab A/S next pay dividends?

Genmab A/S does not currently pay a dividend.

How do I buy Genmab A/S shares?

To buy shares in Genmab A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Genmab A/S?

Shares in Genmab A/S are currently trading at DKK2221, giving the company a market capitalisation of £17.52bn.

Where are Genmab A/S shares listed? Where are Genmab A/S shares listed?

Here are the trading details for Genmab A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: GMAB
What kind of share is Genmab A/S?

Based on an overall assessment of its quality, value and momentum, Genmab A/S is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Genmab A/S share price forecast 2020?

Shares in Genmab A/S are currently priced at DKK2221. At that level they are trading at 0.14% discount to the analyst consensus target price of 0.00.

Analysts covering Genmab A/S currently have a consensus Earnings Per Share (EPS) forecast of 70.879 for the next financial year.

How can I tell whether the Genmab A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genmab A/S. Over the past six months, the relative strength of its shares against the market has been 28.8%. At the current price of DKK2221, shares in Genmab A/S are trading at 13.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Genmab A/S PE Ratio?

The Genmab A/S PE ratio based on its reported earnings over the past 12 months is 25.61. The shares are currently trading at DKK2221.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Genmab A/S?

Genmab A/S's management team is headed by:

Jan van de Winkel - CEO
Anders Pedersen - DRC
Michael Bauer - SVP
Daniel Bruno - DRC
Birgitte Stephensen - SVP
Anthony Pagano - CFO
Pernille Erenbjerg - IND
Martine van Vugt - DHR
Judith Klimovsky - EVP
Peter Storm Kristensen - DRC
Deirdre Connelly - CHM
Tahamtan Ahmadi - SVP
Marisol Peron - VPR
Mijke Zachariasse - DRC
Anthony Mancini - COO
Who are the major shareholders of Genmab A/S?

Here are the top five shareholders of Genmab A/S based on the size of their shareholding:

Artisan Partners Limited Partnership Investment Advisor
Percentage owned: 7.06% (4.63m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.71% (3.09m shares)
Societe Generale SA Corporation
Percentage owned: 4.64% (3.04m shares)
Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund
Percentage owned: 3.96% (2.59m shares)
Vanguard International Growth Fund Mutual Fund
Percentage owned: 3.96% (2.59m shares)
Similar to GMAB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.